NCT02397915 - Patient Preference Study of Fluticasone Furoate and Mometasone Furoate Nasal Sprays | Biotech Hunter

Enrollment

300

Participants

Timeline

Start Date

March 26, 2015

Primary Completion Date

June 8, 2015

Study Completion Date

June 8, 2015

Conditions

Rhinitis, Allergic, Perennial and Seasonal

Interventions

DRUG

FF nasal spray

FF as a suspension for intranasal inhalation with unit dose strength of 27.5 mcg per dose x 4 doses (total dose 110 mcg) administered via a metered side-actuated nasal spray device.

DRUG

MF nasal spray

MF as a suspension for intranasal inhalation with unit dose strength of 50 mcg per dose x 4 doses (total dose 200 mcg) administered via a metered top-actuated nasal spray device.

Trial Locations (12)

2035

GSK Investigational Site, Maroubra

2450

GSK Investigational Site, Coffs Harbour

5500

GSK Investigational Site, Mendoza

6150

GSK Investigational Site, Murdoch

123182

GSK Investigational Site, Moscow

355030

GSK Investigational Site, Stavropol

C1425BEN

GSK Investigational Site, Buenos Aires

C1426ABP

GSK Investigational Site, Buenos Aires

M5500CCG

GSK Investigational Site, Mendoza

405-760

GSK Investigational Site, Incheon

463-707

GSK Investigational Site, Seongnam-si, Gyeonggi-do

08308

GSK Investigational Site, Seoul